Cargando…

Developing a clinical–environmental–genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome

Our inability to reliably predict disease outcomes in multiple sclerosis remains an issue for clinicians and clinical trialists. This study aims to create, from available clinical, genetic and environmental factors; a clinical–environmental–genotypic prognostic index to predict the probability of ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuh-Ngwa, Valery, Zhou, Yuan, Charlesworth, Jac C, Ponsonby, Anne-Louise, Simpson-Yap, Steve, Lechner-Scott, Jeannette, Taylor, Bruce V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691056/ https://www.ncbi.nlm.nih.gov/pubmed/34950873 http://dx.doi.org/10.1093/braincomms/fcab288

Ejemplares similares

The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-centre, longitudinal cohort study
por: Fuh-Ngwa, Valery, et al.
Publicado: (2023)

Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis
por: Fuh-Ngwa, Valery, et al.
Publicado: (2022)

Variation within MBP gene predicts disease course in multiple sclerosis
por: Zhou, Yuan, et al.
Publicado: (2017)

Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset
por: Tao, Chunrong, et al.
Publicado: (2018)

A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study
por: Saul, Alice M, et al.
Publicado: (2023)

Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course
por: Simpson, Steve, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis
por: Chapman, Caron, et al.
Publicado: (2022)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection
por: Pignolo, Antonia, et al.
Publicado: (2021)

Identity-by-Descent Mapping to Detect Rare Variants Conferring Susceptibility to Multiple Sclerosis
por: Lin, Rui, et al.
Publicado: (2013)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
por: Ramanathan, Sudarshini, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Case series: Multiple sclerosis clinical onset and relapse after SARS-CoV-2 Infection
por: Pignolo, Antonia, et al.
Publicado: (2021)

Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis
por: Calvi, Alberto, et al.
Publicado: (2022)

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis
por: Groen, Kira, et al.
Publicado: (2018)

Early red nucleus atrophy in relapse‐onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2020)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

How to run a multiple sclerosis relapse clinic
por: Tallantyre, Emma C, et al.
Publicado: (2016)

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

Association of acute stress with multiple sclerosis onset and relapse in Saudi Arabia
por: AlZahrani, Anwar S., et al.
Publicado: (2019)

Prediction of Conversion from CIS to Clinically Definite Multiple Sclerosis Using Convolutional Neural Networks
por: Afzal, H. M. Rehan, et al.
Publicado: (2022)

Genome-wide DNA methylation changes in CD19(+) B cells from relapsing-remitting multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2018)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Relapse recovery: The forgotten variable in multiple sclerosis clinical trials
por: Kantarci, Orhun H., et al.
Publicado: (2019)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis
por: Staples, Judith, et al.
Publicado: (2010)

Comparison of the sagittal sinus cross-sectional area between patients with multiple sclerosis, hydrocephalus, intracranial hypertension and spontaneous intracranial hypotension: a surrogate marker of venous transmural pressure?
por: Bateman, Grant A., et al.
Publicado: (2017)

Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, Tianrong, et al.
Publicado: (2021)

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis
por: O'Leary, Shirley, et al.
Publicado: (2023)

Is multiple sclerosis a risk factor for infections?
por: Lechner-Scott, Jeannette, et al.
Publicado: (2020)

The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland
por: Brola, Waldemar, et al.
Publicado: (2022)

Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission
por: Arthur, Ariel T, et al.
Publicado: (2008)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ejv5shbv1ipsikl7bvha24dds4